EP4735438A2 - Heterobifunktionelle verbindungen zum kras-abbau - Google Patents

Heterobifunktionelle verbindungen zum kras-abbau

Info

Publication number
EP4735438A2
EP4735438A2 EP24745570.2A EP24745570A EP4735438A2 EP 4735438 A2 EP4735438 A2 EP 4735438A2 EP 24745570 A EP24745570 A EP 24745570A EP 4735438 A2 EP4735438 A2 EP 4735438A2
Authority
EP
European Patent Office
Prior art keywords
compound
independently selected
alkyl
certain embodiments
kras
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24745570.2A
Other languages
English (en)
French (fr)
Inventor
Corey Don Anderson
Xinpeng CHENG
Christopher G. Nasveschuk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of EP4735438A2 publication Critical patent/EP4735438A2/de
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP24745570.2A 2023-06-30 2024-06-27 Heterobifunktionelle verbindungen zum kras-abbau Pending EP4735438A2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363524459P 2023-06-30 2023-06-30
PCT/US2024/035874 WO2025006783A2 (en) 2023-06-30 2024-06-27 Heterobifunctional compounds for the degradation of kras

Publications (1)

Publication Number Publication Date
EP4735438A2 true EP4735438A2 (de) 2026-05-06

Family

ID=91959478

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24745570.2A Pending EP4735438A2 (de) 2023-06-30 2024-06-27 Heterobifunktionelle verbindungen zum kras-abbau

Country Status (3)

Country Link
EP (1) EP4735438A2 (de)
AU (1) AU2024306706A1 (de)
WO (1) WO2025006783A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12448399B2 (en) 2023-01-26 2025-10-21 Arvinas Operations, Inc. Cereblon-based KRAS degrading PROTACs and uses related thereto
CN121941690A (zh) 2023-10-03 2026-04-28 Paq医疗公司 Kras蛋白水解靶向嵌合体
WO2025223215A1 (zh) * 2024-04-24 2025-10-30 重庆华森英诺生物科技有限公司 诱导突变型kras蛋白降解的杂环化合物、其制备方法及应用
TW202547461A (zh) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2738833C9 (ru) 2014-04-14 2022-02-28 Арвинас, Оперэйшнз, Инк. Имидные модуляторы протеолиза и способы их применения
WO2016105518A1 (en) 2014-12-23 2016-06-30 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
EP3270917A4 (de) 2015-03-18 2018-08-08 Arvinas, Inc. Verbindungen und verfahren zum verbesserten abbau von zielproteinen
CA2988414C (en) 2015-06-04 2023-09-26 Arvinas, Inc. Imide-based modulators of proteolysis and associated methods of use
WO2017007612A1 (en) 2015-07-07 2017-01-12 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
BR112017028269A2 (pt) 2015-07-13 2018-09-04 Arvinas Inc composto, composição farmacêutica, uso de uma quantidade efetiva de um composto, estado ou condição de doença, e, método para identificar um composto.
WO2017024318A1 (en) 2015-08-06 2017-02-09 Dana-Farber Cancer Institute, Inc. Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses
WO2017024317A2 (en) 2015-08-06 2017-02-09 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
US10772962B2 (en) 2015-08-19 2020-09-15 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
WO2017117474A1 (en) 2015-12-30 2017-07-06 Dana-Farber Cancer Institute, Inc. Bifunctional compounds for her3 degradation and methods of use
WO2017117473A1 (en) 2015-12-30 2017-07-06 Dana-Farber Cancer Institute, Inc. Bifunctional molescules for her3 degradation and methods of use
ES2990061T3 (es) 2016-05-10 2024-11-28 C4 Therapeutics Inc Degronímeros espirocíclicos para la degradación de proteínas diana
EP3454856B1 (de) 2016-05-10 2024-09-11 C4 Therapeutics, Inc. Heterocyclische degronimere für zielproteinabbau
CN109790143A (zh) 2016-05-10 2019-05-21 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
CN109641874A (zh) 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
JP7327802B2 (ja) * 2017-01-26 2023-08-16 アラクセス ファーマ エルエルシー 縮合ヘテロ－ヘテロ二環式化合物およびその使用方法
IL312367A (en) 2017-01-31 2024-06-01 Arvinas Operations Inc Cereblon ligands and bifunctional compounds comprising the same
JP7227912B2 (ja) 2017-02-08 2023-02-24 ダナ－ファーバー キャンサー インスティテュート，インコーポレイテッド キメラ抗原受容体の調節
AU2018219292B2 (en) 2017-02-08 2024-09-26 Dana-Farber Cancer Institute, Inc. Tunable endogenous protein degradation with heterobifunctional compounds
WO2018226542A1 (en) 2017-06-09 2018-12-13 Arvinas, Inc. Modulators of proteolysis and associated methods of use
CN110769822A (zh) 2017-06-20 2020-02-07 C4医药公司 用于蛋白降解的n/o-连接的降解决定子和降解决定子体
WO2019060742A1 (en) 2017-09-22 2019-03-28 Kymera Therapeutics, Inc AGENTS FOR DEGRADING PROTEINS AND USES THEREOF
CN111372585A (zh) 2017-11-16 2020-07-03 C4医药公司 用于靶蛋白降解的降解剂和降解决定子
WO2019140387A1 (en) 2018-01-12 2019-07-18 Kymera Therapeutics, Inc. Crbn ligands and uses thereof
CA3090417A1 (en) 2018-02-23 2019-08-29 Dana-Farber Cancer Institute, Inc. Small molecules for inducing selective protein degradation and uses thereof
EP3773576A4 (de) 2018-03-26 2021-12-29 C4 Therapeutics, Inc. Cereblon-bindemittel zum abbau von ikaros
WO2019195609A2 (en) 2018-04-04 2019-10-10 Arvinas Operations, Inc. Modulators of proteolysis and associated methods of use
IL302595A (en) 2018-04-13 2023-07-01 Arvinas Operations Inc Servalon ligands and bifunctional compounds containing them
ES3005834T3 (en) 2018-04-16 2025-03-17 Saint Gobain Isover Silicone-coated mineral wool insulation materials and methods for making and using them
EP3578561A1 (de) 2018-06-04 2019-12-11 F. Hoffmann-La Roche AG Spiroverbindungen
CN108876748B (zh) 2018-06-29 2019-08-30 掌阅科技股份有限公司 图片展示方法、计算设备及计算机存储介质
CN120698983A (zh) 2018-12-20 2025-09-26 C4医药公司 靶向蛋白降解
ES2995214T3 (en) 2019-03-06 2025-02-07 C4 Therapeutics Inc Heterocyclic compounds for medical treatment
WO2020210630A1 (en) 2019-04-12 2020-10-15 C4 Therapeutics, Inc. Tricyclic degraders of ikaros and aiolos
KR20220119415A (ko) 2019-12-20 2022-08-29 씨4 테라퓨틱스, 인코포레이티드 Egfr 분해를 위한 이소인돌리논 및 인다졸 화합물
WO2023205701A1 (en) 2022-04-20 2023-10-26 Kumquat Biosciences Inc. Macrocyclic heterocycles and uses thereof
TW202146412A (zh) 2020-03-05 2021-12-16 美商Ｃ４醫藥公司 用於標靶降解brd9之化合物
WO2021255213A1 (en) 2020-06-19 2021-12-23 F. Hoffmann-La Roche Ag Heterobifunctional compounds as degraders of braf
JP2023530030A (ja) 2020-06-19 2023-07-12 シーフォー セラピューティクス， インコーポレイテッド Ｂｒａｆ分解剤
IL300397A (en) 2020-08-05 2023-04-01 C4 Therapeutics Inc Compounds for targeted knockdown of RET
TWI887465B (zh) 2020-08-07 2025-06-21 美商Ｃ４醫藥公司 用於伊卡洛斯(ikaros)或愛露斯(aiolos)介導之病症之有利療法
CN116723839A (zh) 2020-10-14 2023-09-08 C4医药公司 用于降解靶蛋白质的三环杂双官能化合物
MX2023004374A (es) 2020-10-14 2023-07-06 C4 Therapeutics Inc Ligandos tricíclicos para la degradación de la familia ikaros 2 o la familia ikaros 4.
CN115260158A (zh) 2021-04-30 2022-11-01 上海医药集团股份有限公司 一种靶向蛋白调节剂的化合物及其应用
TW202309039A (zh) 2021-05-05 2023-03-01 美商百健Ｍａ公司 用於靶向布魯頓氏酪胺酸激酶降解之化合物
CA3174207A1 (en) 2021-05-26 2022-12-01 Christopher G. Nasveschuck Egfr degraders to treat cancer metastasized to the brain or cns
WO2022251588A1 (en) * 2021-05-27 2022-12-01 Halda Therapeutics Opco, Inc. Heterobifunctional compounds and methods of treating disease
MX2023014059A (es) 2021-06-08 2024-03-12 C4 Therapeutics Inc Terapeuticos para la degradacion de una proteina quiinasa de serina/ treonina mutante.
WO2022266206A1 (en) 2021-06-16 2022-12-22 Erasca, Inc. Kras inhibitor conjugates
CN117460737A (zh) 2021-07-05 2024-01-26 四川科伦博泰生物医药股份有限公司 杂芳环化合物、其制备方法及用途
US20250018046A1 (en) 2021-07-07 2025-01-16 Biogen Ma Inc Compounds for targeting degradation of irak4 proteins
WO2023039208A1 (en) 2021-09-09 2023-03-16 C4 Therapeutics, Inc. Selected compounds for targeted degradation of brd9
CN115785199A (zh) 2021-09-10 2023-03-14 润佳（苏州）医药科技有限公司 一种双官能化合物及其用途
US20250034166A1 (en) * 2021-09-27 2025-01-30 Jacobio Pharmaceuticals Co., Ltd. Polycyclic fused ring derivatives and use thereof
WO2023055952A1 (en) 2021-09-29 2023-04-06 C4 Therapeutics, Inc. Neurotrophic tyrosine receptor kinase (ntrk) degrading compounds
WO2023077441A1 (en) * 2021-11-05 2023-05-11 Ranok Therapeutics (Hangzhou) Co. Ltd. Methods and compositions for targeted protein degradation
CN116332959A (zh) 2021-12-24 2023-06-27 苏州泽璟生物制药股份有限公司 Krasg12d蛋白水解调节剂及其制备方法和应用
CN116375742A (zh) 2021-12-30 2023-07-04 海思科医药集团股份有限公司 一种氮杂芳环衍生物及其组合物和药学上的应用
WO2023141570A2 (en) 2022-01-21 2023-07-27 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of kras
WO2023138524A1 (zh) 2022-01-24 2023-07-27 贝达药业股份有限公司 Kras g12d降解剂及其在医药上的应用
CN116891514A (zh) 2022-04-06 2023-10-17 润佳（苏州）医药科技有限公司 一种双官能化合物及其用途
US20240059712A1 (en) 2022-03-09 2024-02-22 Risen (Suzhou) Pharma Tech Co., Ltd. Bifunctional compounds and pharmaceutical uses thereof
WO2023185864A1 (en) 2022-03-28 2023-10-05 Jingrui Biopharma Co., Ltd. Compounds for Targeted Degradation of KRAS
CR20240451A (es) 2022-04-21 2024-12-04 Gilead Sciences Inc Compuestos de modulación de kras g12d
US20240116951A1 (en) 2022-05-04 2024-04-11 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof
WO2023215802A1 (en) 2022-05-04 2023-11-09 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof
CA3247639A1 (en) 2022-05-06 2023-11-09 PAQ Therapeutics Inc. CHIMERAS TARGET KRAS-G12D PROTEOLYSIS
CA3249074A1 (en) 2022-06-06 2023-12-14 C4 Therapeutics, Inc. BICYCLIC SUBSTITUTION GLUTARIMIDE CEREBLON BINDERS
KR20250023362A (ko) 2022-06-15 2025-02-18 씨4 테라퓨틱스, 인코포레이티드 Smarca2의 표적화된 분해를 위한 화합물
WO2024001839A1 (zh) 2022-06-29 2024-01-04 四川科伦博泰生物医药股份有限公司 杂芳环化合物、其制备方法及用途
US20250145631A1 (en) 2022-07-21 2025-05-08 Astellas Pharma Inc. Heterocyclic compound acting on g12d mutant kras protein
EP4570795A1 (de) * 2022-08-09 2025-06-18 Astellas Pharma, Inc. Heterocyclische verbindung zur induzierung des abbaus des g12v-mutanten kras-proteins
WO2024152247A1 (en) * 2023-01-18 2024-07-25 Nikang Therapeutics , Inc. Bifunctional compounds for degrading kras g12d via ubiquitin proteasome pathway
WO2024054625A2 (en) 2022-09-08 2024-03-14 Nikang Therapeutics, Inc. Bifunctional compounds for degrading kras g12d via ubiquitin proteasome pathway
WO2024050742A1 (en) 2022-09-08 2024-03-14 Nikang Therapeutics, Inc. Bifunctional compounds for degrading kras g12d via ubiquitin proteasome pathway
EP4626554A1 (de) 2022-11-30 2025-10-08 Tiger Biotherapeutics Inc. Glutarimidhaltige kras-mutante degraderverbindungen und verwendungen davon
TW202440597A (zh) 2022-11-30 2024-10-16 美商虎行生物公司 含戊二醯亞胺之pan-kras-突變降解劑化合物及其用途
US20240246963A1 (en) 2022-12-08 2024-07-25 Risen (Suzhou) Pharma Tech Co., Ltd. Bifunctional compounds and pharmaceutical uses thereof
US12448399B2 (en) * 2023-01-26 2025-10-21 Arvinas Operations, Inc. Cereblon-based KRAS degrading PROTACs and uses related thereto

Also Published As

Publication number Publication date
AU2024306706A1 (en) 2026-02-12
WO2025006783A2 (en) 2025-01-02
WO2025006783A3 (en) 2025-02-20

Similar Documents

Publication Publication Date Title
US12049464B2 (en) Compounds for targeted degradation of BRD9
EP4735438A2 (de) Heterobifunktionelle verbindungen zum kras-abbau
US11673902B2 (en) Isoindolinone and indazole compounds for the degradation of EGFR
EP4735452A2 (de) Heterobifunktionelle verbindungen zum abbau des kras-proteins
US20230233692A1 (en) Compounds for targeted degradation of ret
TW202313628A (zh) 用於降解突變braf之治療劑
US20240158418A1 (en) EGFR Degraders to Treat Cancer Metastasis to the Brain or CNS
WO2025137605A1 (en) Compounds for targeted degradation of proto-oncogene tyrosine protein kinase receptor
WO2024097980A1 (en) Ret-ldd protein inhibitors

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE